Home › Anterior Cruciate Ligament Injuries › NCT05412381
PRP in ACLR to Prevent PTOA
Platelet Rich Plasma (PRP) Treatment of the Anterior Cruciate Ligament Injured Knee to Decrease the Risk of Post-traumatic Osteoarthritis (PTOA): a Randomized Double-blind Controlled Trial
Who can join
Ages 14 to 50 · All sexes
Full eligibility criteria
Inclusion Criteria: * Acute ACL injury within 6 weeks of presentation * Age 14-50 * Male or female * Meniscus injury that can be treated with meniscectomy or repair (the lack of meniscus injury will not exclude patients) Exclusion Criteria: * Prior ACL reconstruction * Prior cartilage repair procedure * Prior meniscus surgery within 12 months * Prior steroid, hyaluronic acid, or PRP injection within 6 months * Other ligament injury requiring repair * Any cartilage lesion requiring repair * Any cartilage lesion greater than grade 2 (partial thickness injury) * History of inflammatory arthritis or joint sepsis * Non English speakers
About the study
The purpose of our study is to examine the effect of platelet-rich-plasma (PRP) injection on the short-term resolution of post-injury inflammation (biomarkers) and improvement in joint function in patients with acute ACL injury. This RCT has been powered based on the questionnaire KOOS Jr. but it is considered a 'pilot study' in terms of the lab analysis proposed.
What is being tested
- platelet rich plasma (PRP) injection (procedure)
- placebo saline injection (procedure)
Sponsor: Hospital for Special Surgery, New York · Participants: 56 · Started: Jun 27, 2022
Contact the study team
- Jessica Andres-Bergos, PhD · Phone: (917) 260-4694
Official record on ClinicalTrials.gov — NCT05412381
Locations in the U.S.
| New York | Hospital for Special Surgery, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.